Breast Cancer Clinical Trial
Official title:
Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach
RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One
type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect
the growth of abnormal breast cells.
PURPOSE: This randomized pilot trial is studying how well omega-3 fatty acids work in
treating women with newly diagnosed ductal carcinoma in situ and/or atypical ductal
hyperplasia.
OBJECTIVES:
- To determine the effect of omega-3 fatty acids on markers of breast cancer progression
in women with newly diagnosed ductal carcinoma in situ and/or atypical ductal
hyperplasia.
- To determine the effect of omega-3 fatty acids on specific targets identified by
microarray in breast cancer cells and in primary cultures from benign and malignant
breast tissue biopsies.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8
weeks.
- Arm II: Patients receive oral placebo olive oil capsules 3 times daily for up to 8
weeks.
Patients complete questionnaires at baseline, weekly during study treatment, at the
completion of study treatment, and then at 30 days after completion of study treatment.
These questionnaires include the Fish Oil Adverse Event Questionnaire, the Diet and Family
History Questionnaire, the Changes to Diet and Medications Questionnaire, and the
Post-Intervention Questionnaire.
Patients undergo blood, urine, nipple aspirate, and tissue sample collection at baseline and
after completion of study treatment for translational research studies. Blood samples are
analyzed for genetic markers for breast cancer risk and progression by microarray analysis
and red blood cell (RBC) fatty acids. Nipple aspirate samples are analyzed for fatty acids
to determine the extent to which omega-3 fatty acid supplementation alters the fatty acid
profile of breast tissue. Tissue samples are analyzed for the presence of ductal carcinoma
in situ and/or atypical ductal hyperplasia or invasive cancer. Leftover blood, urine, nipple
aspirate, and tissue samples are stored for future research studies.
After completion of study treatment, patients are followed at 30 days.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |